N-[2-[2-(4-Fluorophenyl)ethyl]-5-[[[(2S,4S)-4-[(3-pyridinylcarbonyl)thio]-2-pyrrolidinyl]methyl]amino]benzoyl]-L-methionine 1-methylethyl ester
AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.